Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
25.83
+2.36 (10.06%)
At close: Oct 8, 2025, 4:00 PM EDT
25.83
0.00 (0.00%)
After-hours: Oct 8, 2025, 4:00 PM EDT
Neurogene Employees
Neurogene had 107 employees as of December 31, 2024. The number of employees increased by 16 or 17.58% compared to the previous year.
Employees
107
Change (1Y)
16
Growth (1Y)
17.58%
Revenue / Employee
n/a
Profits / Employee
-$788,729
Market Cap
368.64M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 107 | 16 | 17.58% |
| Dec 31, 2023 | 91 | 9 | 10.98% |
| Dec 31, 2022 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NGNE News
- 14 hours ago - Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference - Business Wire
- 5 days ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire
- 2 months ago - What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
- 3 months ago - Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - Business Wire
- 5 months ago - Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV - Business Wire
- 5 months ago - Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire
- 5 months ago - Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting - Business Wire